1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6F21F1A8B893EFBD365257F5700288AD3
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/disease-awareness-program-excellence-structure-activities-resources-needed-effective-pipeline-support?opendocument
18
19opendocument
203.80.4.76
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Product Launch Influences on Market Entry

Disease Awareness Program Excellence: Structure, Activities & Resources Needed for Effective Pipeline Support

ID: PSM-328


Features:

12 Info Graphics

28 Data Graphics

400+ Metrics

28 Narratives

17 Best Practices


Pages: 73


Published: 2016


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
In the global healthcare marketplace, it is critical for pharmaceutical companies to effectively communicate information to external stakeholders such as physicians, patients and payers.


Disease state awareness campaigns have long been used by the industry to disseminate unbranded information about the characteristics of a particular disease, and how it affects patients. With unbranded education among the most trusted sources of information for HCPs and patients, it is vital that pharmaceutical organizations effectively utilize their disease awareness programs to support pipeline portfolio products.

This research provides reliable industry metrics on current disease state awareness program structure, spend, and activities that support pipeline products. In addition, the study reviews the timing of disease state awareness activities.


Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Consumer Products; Diagnostic; Medical Device; Biopharmaceutical; Public Relations; Health Care


Companies Profiled:
Abbvie; Adamas Pharmaceuticals; AstraZeneca; Biogen; Bayer; Catalyst Pharmaceuticals; FleishmanHillard; Fresenius Medical Care AG & Co. KGaA; Genzyme; Indivior; Lilly; Merck; Novartis; Prometheus Therapeutics & Diagnostics; Tokai Pharmaceuticals; Vertex Pharmaceuticals; ZS Pharma

Study Snapshot

Best Practices, LLC engaged 17 executives from leading pharmaceutical, biotech, and communications companies through a benchmarking survey to explore best practices around the timing, investment, and activities for disease awareness programs.

Key Findings

Marketing is Primary Contributor for Disease Awareness Programs: Most participants (64%) rely on marketing as the principal funding source for disease awareness. Brand teams were second, with 46% saying they were the primary contributor.
Patient Advocacy Groups Seen as Valuable Partners: Almost 80% of study participants think it is highly important to create alliances with patient advocacy groups. At the same time, a majority also felt it is highly important to build relationships with key advocates and work on disease awareness websites/campaigns for/with advocacy groups.

Disease Awareness Activities and Spend are Concentrated on Launch -1 Year & Launch Year : It is during the launch -1 year and launch year periods that a majority of participants conduct the eight key disease awareness activities measured in this study; participants spend 50% of their budget during these two periods.

Table of Contents

Executive Summary, pgs. 4-8
Research Overview, pg. 4

Participating Companies, pg. 5

Key Findings Overview, pg. 6

Key Insights Overview, pg. 7

Overview of DA Timing, pgs. 8

I. Participant Demographics, pgs. 9-13

II. Program Effectiveness and Structure, pgs. 14-19

III. Timing of Disease Awareness Activities, pgs. 20-27

IV. Disease Awareness Budget and Spend, pgs. 28-36

V. Involvement of Advocacy and Legal, pgs. 37-45

VI. Social Media, pgs. 46-53

VII. Best Practices and Pitfalls, pgs. 54-56

VIII. Narratives from Interviews, pgs. 57-66

VIIII. Key Findings, pgs. 67-72

X. Appendix, pgs. 73-78

About Best Practices, LLC, pg. 79


List of Charts & Exhibits

Disease Awareness (DA) Program Effectiveness
Disease Awareness Organizational Structure
Functional Involvement & Leadership in DA
Presence of Distinct Disease Awareness Group
Start and End Point of Disease Awareness Efforts
Timing for Disease Awareness Activities
Most Heavily Used Disease Awareness Activities
Factors Influencing the Amount of Resources Dedicated to Disease Awareness Programs on a Product-by-Product Basis
Percentage of Peak-year Sale Projections Spent on the Disease State Awareness Program for a Typical Product Across its Entire Lifecycle
Company-Wide Budget for Disease Awareness Initiatives, Activities and Programs
Functions Providing Funding for Disease Awareness Programs
Peak Investment Year for Disease Awareness Initiatives
Percentage of Total Disease Awareness Budget for a New Product Allocated to Different Product Stages
Peak Year Investment for Disease Awareness
Additional Disease Awareness Investment Needed for Unmet Need Products
Importance Level of DA Activities with Advocacy Groups
Keys to Developing a Good Relationship with Advocacy
Approaches to Support Disease Awareness Activities with Patient Advocacy Groups
Timing of Disease Awareness Activities with Patient Advocacy Groups
Level of Involvement of the Organization's Legal Department in Different Disease Awareness Program Areas
Legal Review Requirements for Key Markets
Disease State Awareness (DSA) Social Media Activities
Patient Access via Social media
Utilization Ranking of Social Media Activities
Social Media Spend for Disease Awareness
Social Media DA Spend and Percentage of DA Budget
Best Practices for Maintaining An Effective Disease State Awareness Program
Pitfalls To An Effective Disease Awareness Program